Literature DB >> 24636641

Evaluation of Medicare claims data to ascertain peripheral vascular events in the Women's Health Initiative.

Matthew W Mell1, Mary Pettinger2, Lori Proulx-Burns2, Susan R Heckbert3, Matthew A Allison4, Michael H Criqui4, Mark A Hlatky5, Dale R Burwen6.   

Abstract

OBJECTIVE: Capturing long-term outcomes from large clinical databases by use of claims data is a potential strategy for improving efficiency while reducing study costs. We sought to compare the use of Medicare data with data from the Women's Health Initiative (WHI) to determine peripheral vascular events, as defined by the WHI study design.
METHODS: We studied participants from the WHI with both adjudicated outcomes and links to Medicare enrollment and utilization data through 2007. Outcomes of interest included hospitalizations for treatment of abdominal aortic aneurysm (AAA), lower extremity peripheral artery disease (LE PAD), and carotid artery stenosis (CAS). Events determined by WHI adjudication were compared with events defined by coding algorithms using diagnosis and procedure codes from Medicare data with a pilot data set and then validated with a test data set. We assessed agreement by a κ statistic and evaluated reasons for disagreement.
RESULTS: In the pilot set, records from 50,511 participants were analyzed. Agreement between the Centers for Medicare and Medicaid Services and WHI for admissions with a diagnosis but no treatment procedures for vascular conditions was poor (κ, 0.02-0.18). On the basis of WHI outcome data collection, vascular treatment procedures occurred in 29 participants for AAA, 204 for LE PAD events, and 281 for CAS. Medicare hospital claims recorded 41 treatments for AAA, 255 for LE PAD, and 317 for CAS. For participants with a Centers for Medicare and Medicaid Services-captured vascular procedure and a record adjudicated by WHI, κ values for treatment procedures were 0.81 for AAA, 0.77 for PAD, and 0.93 for CAS. For vascular procedures identified by WHI but not by Medicare hospital data (n = 82), 55% were captured by Medicare physician claims. Conversely, for treatments identified by Medicare hospital data but not captured by WHI adjudication (n = 57), 74% had physician claims consistent with the procedure. Fifteen participants with AAA or LE PAD procedures in hospital claims had medical records available for review, and nine of these had definitive documentation of procedures that were not captured by the WHI adjudication process. Estimated positive predictive value of Medicare data was 91% to 94% for AAA, 92% to 95% for LE PAD, and 94% to 99% for CAS. Available test set data (n = 50,253) yielded generally similar results with κ of 0.77 for AAA, 0.79 for LE PAD, and 0.94 for CAS.
CONCLUSIONS: Medicare data appear useful for identifying vascular treatment procedures for WHI participants. Medicare hospital claims identify more procedures than WHI does, with high positive predictive value, but also may not capture some procedures identified in WHI.
Copyright © 2014. Published by Mosby, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24636641     DOI: 10.1016/j.jvs.2014.01.056

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  11 in total

1.  Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials.

Authors:  Jacqueline B Shreibati; JoAnn E Manson; Karen L Margolis; Rowan T Chlebowski; Marcia L Stefanick; Mark A Hlatky
Journal:  Am Heart J       Date:  2017-12-27       Impact factor: 4.749

Review 2.  Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Authors:  Lori M Minasian; Catherine M Tangen; D Lawrence Wickerham
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

3.  Smartphone-Based Geofencing to Ascertain Hospitalizations.

Authors:  Kaylin T Nguyen; Jeffrey E Olgin; Mark J Pletcher; Madelena Ng; Leanne Kaye; Sai Moturu; Rachel A Gladstone; Chaitanya Malladi; Amy H Fann; Carol Maguire; Laura Bettencourt; Matthew A Christensen; Gregory M Marcus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-03

4.  Sustained Posttransplantation Diabetes Is Associated With Long-Term Major Cardiovascular Events Following Liver Transplantation.

Authors:  G A Roccaro; D S Goldberg; W-T Hwang; R Judy; A Thomasson; S E Kimmel; K A Forde; J D Lewis; Y-X Yang
Journal:  Am J Transplant       Date:  2017-07-27       Impact factor: 8.086

5.  Women's Health Initiative Strong and Healthy (WHISH): A pragmatic physical activity intervention trial for cardiovascular disease prevention.

Authors:  Marcia L Stefanick; Charles Kooperberg; Andrea Z LaCroix
Journal:  Contemp Clin Trials       Date:  2022-06-09       Impact factor: 2.261

6.  Use of administrative data to increase the practicality of clinical trials: Insights from the Women's Health Initiative.

Authors:  Garnet L Anderson; Carolyn J Burns; Joseph Larsen; Pamela A Shaw
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

7.  Regional Variation in Rates of Total Knee Arthroplasty Among Medicare Beneficiaries.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  JAMA Netw Open       Date:  2020-04-01

8.  Lipoprotein(a) levels and risk of abdominal aortic aneurysm in the Women's Health Initiative.

Authors:  Elizabeth L Chou; Mary Pettinger; Bernhard Haring; Matthew W Mell; Mark A Hlatky; Jean Wactawski-Wende; Matthew A Allison; Robert A Wild; Aladdin H Shadyab; Robert B Wallace; Linda G Snetselaar; Matthew J Eagleton; Mark F Conrad; Simin Liu
Journal:  J Vasc Surg       Date:  2020-08-31       Impact factor: 4.268

9.  Younger patients with chronic limb threatening ischemia face more frequent amputations.

Authors:  E Hope Weissler; Cassie B Ford; Manesh R Patel; Phil Goodney; Amy Clark; Chandler Long; W Schuyler Jones
Journal:  Am Heart J       Date:  2021-08-08       Impact factor: 4.749

10.  Long-term metabolic risk for the metabolically healthy overweight/obese phenotype.

Authors:  A E Espinosa De Ycaza; D Donegan; M D Jensen
Journal:  Int J Obes (Lond)       Date:  2017-09-25       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.